As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Source
No articles found.
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel pr...
Novavax, Inc. is a clinical-stage vaccine compa...
Founded in 2014 in Miami, Florida, HeartIn Inc. is constantly driving innovations ...
Founded in 2014 in Miami, Florida, HeartIn Inc....
EyeGate is developing and commercializing products for treating diseases and disor...
EyeGate is developing and commercializing produ...
BioSculpture Technology, Inc. (âBSTâ) is a commercial-stage medical device man...
BioSculpture Technology, Inc. (âBSTâ) is a ...
T2 Biosystems, a leader in the development and commercialization of innovative med...
T2 Biosystems, a leader in the development and ...
CHF Solutions is focused on improving the quality of life for patients suffering f...
CHF Solutions is focused on improving the quali...
Precision BioSciences is dedicated to improving life (DTIL) through its proprietar...
Precision BioSciences is dedicated to improving...
Join the National Investor Network and get the latest information with your interests in mind.